APA (7th ed.) Citation

T, W., K, M., S, N., H, S., T, K., T, H., . . . N, T. (2025). First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial). Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 66(12), 1941. https://doi.org/10.2967/jnumed.125.270810

Chicago Style (17th ed.) Citation

T, Watabe, et al. "First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 66, no. 12 (2025): 1941. https://doi.org/10.2967/jnumed.125.270810.

MLA (9th ed.) Citation

T, Watabe, et al. "First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 66, no. 12, 2025, p. 1941, https://doi.org/10.2967/jnumed.125.270810.